Cocrystal receives approval from HREC for Phase I trial

Committee (HREC) to initiate a Phase I trial of CDI-988 for the treatment of Covid-19.

CDI-988 is an oral, broad-spectrum 3CL protease inhibitor designed using Cocrystal’s proprietary drug discovery platform technology.

The double-blind, randomised, dose-escalating, placebo-controlled study aims to to evaluate CDI-988’s tolerability, safety, and pharmacokinetics in healthy volunteers.

In August last year, Cocrystal Pharma selected hVIVO as a contract research organisation to conduct a Phase IIa human challenge trial of its oral antiviral candidate, CC-42344, for Influenza A.

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    Versatile MDCK cells in research and biotechnology

    MDCK (Madin-Darby Canine Kidney) cells are an essential tool in biological and medical research, especially in virology, cell biology, and studies involving membrane transport. Originally derived in 1958 from the kidney of a healthy adult female

    hVIVO plc

    Exploring the human viral challenge model for influenza research

    This study evaluates the human viral challenge model using the A/Perth/16/2009 H3N2 influenza virus, involving 216 volunteers across five clinical studies. Administered intranasally under controlled conditions, the research aimed to improve the understanding of influenza infection

    hVIVO plc

    Advancing influenza research with new challenge agents

    Controlled Human Infection Studies (CHIS) have proven to be essential in exploring human responses to respiratory infections and testing the effectiveness of vaccines and treatments. These studies hinge on selecting an appropriate challenge virus, making a

    hVIVO plc

    hVIVO’s patient enrolment & retention at Canary Wharf

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Inside hVIVO’s cutting-edge QA facility at Canary Wharf

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Virus portfolio for RSV research and development

    Respiratory Syncytial Virus (RSV), discovered in 1956, is a common and contagious RNA virus responsible for a range of respiratory illnesses worldwide. Initially identified by Dr. Robert Chanock and colleagues in chimpanzees, RSV belongs to the

    hVIVO plc

    Clinical trial eligibility: Pre-screening and Screening

    In clinical trials, ensuring patient safety is paramount, and researchers must identify suitable participants who meet specific requirements. To this end, there are distinct processes involved, known as pre-screening and screening, which help determine whether a

    hVIVO plc

    Connecting Airway Epithelial Cell Models with Human Challenge Studies

    Airway epithelial cells cultured in Air–Liquid Interface (ALI) conditions provide an environment that closely resembles the human airway system. This method facilitates improved oxygen availability and supports cellular differentiation, replicating the physiological conditions of the human

    hVIVO plc

    Esmée shares her FluCamp clinical trial volunteer experience

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Overcoming challenges in high-growth regulated industries

    The Navigating Risk podcast recently explored the challenges faced by high-growth businesses operating in highly regulated industries, particularly life sciences. Helen Yates, the Editor of Global Thought Leadership, engaged in a conversation with Mo Khan, the

    hVIVO plc

    Take a 360° interactive tour of a FluCamp Volunteer Room

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Clinical trial approval process in the UK

    The process of obtaining approval for clinical trials is comprehensive, as it involves multiple regulatory bodies that ensure the safety and efficacy of the medical interventions being tested. Researchers begin by meticulously planning the trial, outlining

    hVIVO plc

    hVIVO reports positive results from RSV antiviral human challenge trial

    hVIVO plc (LON:HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has noted the announcement by Enanta Pharmaceuticals, reporting positive topline results from